London, UK, 7 November 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Richard Jones, Chief Financial Officer, will leave the Group in early 2017 to pursue a new opportunity. Until his departure Richard will continue as a Board member and Shield’s Chief Financial Officer, with a focus on progressing key commercialisation workstreams as well as facilitating an orderly transition. A further announcement regarding the appointment of a new Chief Financial Officer will be made in due course.
Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: “Richard has helped build the Group from its inception as a small private company through to being listed on AIM. I would like to thank him for his significant contribution to Shield and wish him the best in his future endeavours as we continue to grow rapidly into a commercial-stage specialty pharmaceutical business with international operations.”
Richard Jones added: “I have thoroughly enjoyed my six and a half years of service to Shield, working with Carl and the team, and I am very proud of what we have achieved. It is now time to apply my skills to a new challenge.”
